180 Life Sciences Corp. (Nasdaq: ATNF) — Q1 2024 Form 10-Q
Filing identity: The supplied filing is for 180 Life Sciences Corp., not FORUM MARKETS Inc. It covers the three months ended March 31, 2024; the statements are unaudited. The company is a clinical-stage biotechnology business with no revenue to date.
Financial results and position
| Metric | Q1 2024 / March 31, 2024 | Comparable period / December 31, 2023 |
|---|---|---|
| Revenue | None reported | None reported |
| Operating expenses | $2.09 million | $4.80 million in Q1 2023 |
| Operating loss | $2.09 million | $4.80 million in Q1 2023 |
| Net loss | $1.07 million; $1.68 per basic and diluted share | $4.76 million; $24.15 per share in Q1 2023 |
| Operating cash flow | $(1.03) million | $(3.87) million in Q1 2023 |
| Cash | $676,000 | $1.98 million at December 31, 2023 |
| Working capital | $(2.23) million | $(1.42) million at December 31, 2023 |
| Total loans payable | $789,000, including $772,000 current and $17,000 noncurrent | $1.05 million at December 31, 2023 |
| Total liabilities / assets | $4.40 million / $3.44 million | $5.39 million / $5.26 million at December 31, 2023 |
Gross profit and operating margins are not meaningful because the company reported no revenue. The 78% reduction in net loss was driven by lower expenses and $1.04 million of other income from forgiveness of contractor amounts related to R&D programs; it does not reflect product revenue. Operating expenses fell 56% overall: R&D and related-party R&D costs declined, while general and administrative expense decreased 61%, principally due to lower legal, accounting/regulatory, salary, and stock-compensation costs. The company repaid $265,000 of loans during the quarter.
Business, outlook, and material developments
- Programs target fibrosis/anti-TNF, cannabinoid-derived compounds, and the alpha-7 nicotinic acetylcholine receptor. Due to limited resources, R&D on the first two platforms has slowed significantly; the third program is suspended.
- Management is evaluating ways to monetize assets and other strategic alternatives, including a sale, licensing, merger, or other business combination. No transaction or product-revenue guidance is provided.
- The company reported an accumulated deficit of $128.4 million and stated that substantial doubt exists about its ability to continue as a going concern. It estimated a minimum monthly cash requirement of about $300,000 and said cash on hand of approximately $1.5 million as of May 13, 2024, together with subsequent insurance receipts, was expected to fund operations through October 2024. Additional financing is needed and may be dilutive or unavailable on acceptable terms.
- Subsequent to quarter-end, AmTrust paid $2.27 million on April 16 and $300,140 on May 9 as reimbursements for certain advancement expenses; the company reported net receipts or expected net receipts after legal fees of $1.5 million and $200,093, respectively. These payments are interim and remain subject to ongoing litigation; a final judgment could require repayment.
- Nasdaq minimum-bid-price compliance was regained in March. However, the company did not meet the stockholders’ equity requirement by May 13 and received a delisting determination letter on May 14. It intended to request a hearing, which was expected to stay delisting pending the process. Nasdaq also notified it of audit-committee composition noncompliance; a cure period applies. Neither compliance nor continued listing is assured.
- A 1-for-19 reverse stock split became effective February 28, 2024. Common shares outstanding were 852,772 at March 31 and 941,590 as of May 15. The filing describes substantial outstanding warrants, including 954,118 warrants with a $3.23 exercise price.
- On May 7, CEO James Woody and CSO Jonathan Rothbard resigned; Blair Jordan became interim CEO. The filing describes related separation, consulting, and contingent compensation arrangements.
- Disclosure controls were deemed ineffective at March 31 because of a material weakness involving the classification of reversals of accrued bonuses for a discontinued R&D project. Management added a technical review step and planned further remediation assessment in the second half of 2024.
- Significant litigation includes disputes involving former executives, Tyche Capital, the Bauers, and D&O insurers. Outcomes and recoveries are uncertain; the filing recorded no liability for loss contingencies at March 31.
Most important facts for investors to verify
- Whether the company obtained additional financing or completed strategic transactions, and whether its stated runway through October 2024 remained achievable.
- The outcome of the Nasdaq hearing, minimum-equity compliance efforts, and audit-committee remediation; confirm the current trading and listing status of ATNF and its warrants.
- Whether further insurance reimbursements are received and retained, and the ultimate judgment and appeal status in the insurer litigation.
- Whether R&D remains substantially curtailed, whether any platform advances, and whether any licensing, asset-sale, merger, or other strategic transaction is announced.
- Changes in outstanding shares, warrant exercises, and potential dilution; reconcile the reported quarter-end and May 15 share counts with subsequent issuances.
- Progress in remediating the material weakness and any updates to liquidity, going-concern disclosures, or litigation contingencies.